What is the proper use and dosage of Ivermectin for treating parasitic infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ivermectin Dosage and Administration for Parasitic Infections

For treating parasitic infections, oral ivermectin should be administered at a dose of 200 μg/kg (micrograms per kilogram) body weight, taken with food to increase bioavailability, with a second dose administered 14 days after the first dose to ensure complete eradication. 1, 2

Standard Dosing for Common Parasitic Infections

Strongyloidiasis

  • Single oral dose of 200 μg/kg body weight 2
  • Take tablets with food to increase bioavailability and drug penetration into the epidermis 1
  • Follow-up stool examinations should be performed to verify eradication 2

Scabies (Regular)

  • 200 μg/kg orally, repeated in 2 weeks 1
  • Second dose is necessary because ivermectin has limited ovicidal activity and may not prevent recurrences from eggs present at the time of treatment 1
  • Not recommended for children weighing less than 15 kg 1

Crusted Scabies (Norwegian Scabies)

  • More aggressive dosing regimen required due to higher parasite burden 1
  • Combination treatment recommended with:
    • Oral ivermectin 200 μg/kg on days 1,2,8,9, and 15 1
    • Additional doses on days 22 and 29 may be required for severe cases 1
    • Plus topical scabicide (5% permethrin cream or 5% benzyl benzoate) applied daily for 7 days then twice weekly until cure 1

Pediculosis Pubis (Pubic Lice)

  • 250 μg/kg repeated in 2 weeks 1
  • Alternative to first-line topical treatments when they fail 1

Special Populations and Considerations

Pregnancy

  • Ivermectin is classified as "human data suggest low risk" in pregnancy 1
  • Likely compatible with breastfeeding 1

Children

  • Safety not established in children weighing less than 15 kg 1
  • For head lice in children, ivermectin should not be used for children weighing less than 15 kg due to risk of crossing blood-brain barrier 1

Renal Impairment

  • No dosage adjustments required in patients with renal impairment 1

Hepatic Impairment

  • Safety of multiple doses in patients with severe liver disease is not known 1
  • Use with caution in patients with severe hepatic disease 1

Administration Guidelines

  • Take with food to increase bioavailability 1
  • For strongyloidiasis: See weight-based dosing table 2:
    • 15-24 kg: 1 tablet (3 mg)
    • 25-35 kg: 2 tablets
    • 36-50 kg: 3 tablets
    • 51-65 kg: 4 tablets
    • 66-79 kg: 5 tablets
    • ≥80 kg: Calculate 200 μg/kg

Treatment Efficacy and Safety

  • Ivermectin is effective against various parasites including strongyloidiasis, scabies, and some protozoal infections 3, 4
  • For strongyloidiasis, a 2-day regimen (200 μg/kg daily for 2 consecutive days) has shown 100% cure rate compared to 77% with single-day treatment 5
  • Common side effects include:
    • Mild and short-duration effects such as edema, rash, headache 6
    • Pruritus may persist for up to 2 weeks after treatment due to allergic reaction to dead parasites 1

Important Precautions

  • Exclude Loa loa infection in people who have traveled to endemic regions BEFORE treating with ivermectin 1
  • Ivermectin is a substrate for P-glycoprotein; genetic polymorphisms or co-administration of P-glycoprotein inhibitors may increase neurotoxicity risk 6
  • Bedding and clothing should be decontaminated (machine-washed and dried using hot cycle) or removed from body contact for at least 72 hours 1
  • Retreatment after 2 weeks should be considered for patients who remain symptomatic or when live parasites are still observed 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

The effect of ivermectin on Cryptosporidium parvum in experimentally infected rat.

Journal of the Egyptian Society of Parasitology, 2000

Research

Ivermectin: a mini-review.

Clinical toxicology (Philadelphia, Pa.), 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.